Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Healthcare Biotechnology
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Knight Therapeutics Inc > Halt ... just a shuffle
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon May 13, 2021 4:35pm
128 Views
Post# 33197008

RE:RE:RE:RE:RE:RE:RE:Halt ... just a shuffle

RE:RE:RE:RE:RE:RE:RE:Halt ... just a shuffle
Chianchin wrote: Kudos to Benedict, he predicted that the market was demanding heads to roll and they got one. With all due respect Mr. JG failled and badly sevemn waisted years regardless of any public  spin the do, If the share price re,main in limbo  the market will demand all heads to roll and so they should if they contine to fail.  Great day.Meir must be smiling today. Poetic Justice but late coming 


Wrong !!!  Nice try Chi-Chi but heads didn't roll.

Samira gets the job she signed up for and Goodman continues to stratgically guide the ship.
Their work relationship doesn't really change.

==================

Definition (general) ... The Chairperson's main duties include chairing meetings of the Board of Directors, setting meeting agendas in conjunction with the Company Secretary, managing and providing leadership to the Board of Directors, and acting as a direct liaison between the Board and the Company's management, through the Chief Executive ...
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities